

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53578

**Title:** Immune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: A pilot study

**Reviewer's code:** 02942954

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2019-12-25

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2019-12-26 14:08

**Reviewer performed review:** 2019-12-29 08:14

**Review time:** 2 Days and 18 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This manuscript compared the differences in the absolute number of several immune cells between pre- and post-operation, in order to investigate the effects of hyperthermic intraperitoneal chemotherapy on immune responses. It is interesting, but some questions remained to be solved. 1. For the title, the abbreviation “HIPEC” should be avoided. 2. Paired chi-square or t tests may be more suitable for your data. 3. If convenient, please provide the representative dot plots of flow cytometry and the frequency of various cell types in lymphocyte.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53578

**Title:** Immune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: A pilot study

**Reviewer's code:** 02974589

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Profeesor

**Reviewer's Country/Territory:** Sweden

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2019-12-25

**Reviewer chosen by:** Ruo-Yu Ma

**Reviewer accepted review:** 2020-03-31 09:37

**Reviewer performed review:** 2020-03-31 10:15

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

1: Abstract: I would change "the immune reaction" to "an immune reaction" since there are many different types of immune responses. 2: Many people in the field advocate for changing from peritoneal carcinomatosis to peritoneal metastases. Carcinomatosis means "cancer transformation" of the peritoneum and we hope to change this view of the peritoneum. To see peritoneal surface disease as a locoregional metastatic disease in much the same way as the liver is. My suggestion is to change this term throughout the article and use peritoneal metastases or peritoneal metastatic disease or something likewise instead. 3: Abstract – take away the first instance of "on" in the first sentence of the abstract 4: Introduction – page 4 – in the beginning of page 4 a sentence ends abruptly "systemic bloodstream of ...." Please complete sentence. 5: Introduction – page 4 – RFA is not explained in the introduction. Please write out the first instance of acronyms. 6: Methods – The abstract and methods sections don't say the same thing. As I read the abstract, I interpret the method section there to mean that blood samples were taken 1 time preoperatively and then 3 times postoperative on postop day 1, 3, and 30. That means 4 samples per patient. However, in the main text methods, samples were taken day 0 and day 30 which isn't the same. Day 0 is that the same day as the HIPEC procedure then? Please clarify very specifically when the preop sample was taken and exactly when the postop samples were taken. The methods in the abstract needs to match the methods in the main text file. 7: Please indicate in table two which tests that were statistically increased from baseline to post-HIPEC. 8: Please indicate which sample time was used in the post HIPEC results (was it 30 days). 9: In the discussion, a recommendation of at least 60 minutes of hyperthermia was given. However, this study does not provide the basis for such a recommendation (there was no comparison between different hyperthermia times). Please remove this recommendation and only



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

make conclusions on the data that has been acquired. 10: In general the language needs editing. There are a number of incorrect spellings such as “cytoreduction” and “oxalyplatin”. Also a number of grammatical errors that need language editing. 11: The discussion has a short paragraph touching on the issue of surgical trauma. Are there any good articles to reference for this. Because this study only looked at the combination CRS+HIPEC. It would have been nice to have a few patients with only CRS without HIPEC in order to be able to see if there is an actual HIPEC related immune response. As the study is set up now, you can only evaluate the combination of CRS+HIPEC. Thus, it is difficult to say for sure that this immune stimulation is HIPEC related. It may actually be CRS related. Please comment a little more on this. Perhaps seeing if there is any relevant literature that has looked into the immune response after just surgical trauma. 12: The overall conclusion is good with the need of a larger study to really evaluate the HIPEC effect and not the CRS effect on the immune response.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53578

**Title:** Immune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: A pilot study

**Reviewer's code:** 03769068

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Brazil

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2019-12-25

**Reviewer chosen by:** Ruo-Yu Ma

**Reviewer accepted review:** 2020-03-31 10:47

**Reviewer performed review:** 2020-04-01 22:34

**Review time:** 1 Day and 11 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The study is interesting, despite the small number of patients. 1) I don't think it's appropriate to use the term immune reaction. 2) The results of the abstract need to be better described. 3) I believe that in the conclusion (abstract) the authors should mention that more studies need to be done. 4) The flow cytometry methodology needs to be detailed. 5) Was a normality test performed to apply the t test? 6) I believe that the results deserve to be better presented. 7) The authors in the discussion need to assume the limitations of the study. 8) I think it's important that the authors put images resulting from flow cytometry. 9) The use of graphics would be interesting. 10) The purposes of the statistical tests employed are not clear.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53578

**Title:** Immune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: A pilot study

**Reviewer's code:** 00009760

**Position:** Editorial Board

**Academic degree:** MD, FRCS (Ed)

**Professional title:** Professor

**Reviewer's Country/Territory:** Australia

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2019-12-25

**Reviewer chosen by:** Ruo-Yu Ma

**Reviewer accepted review:** 2020-03-31 23:48

**Reviewer performed review:** 2020-04-07 04:45

**Review time:** 6 Days and 4 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



## SPECIFIC COMMENTS TO AUTHORS

This paper describes positive changes in immunological function post CRS + HIPEC.  
This is interesting. A small number of patients.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53578

**Title:** Immune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: A pilot study

**Reviewer's code:** 02942954

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2019-12-25

**Reviewer chosen by:** Jie Wang

**Reviewer accepted review:** 2020-04-17 17:36

**Reviewer performed review:** 2020-04-18 02:48

**Review time:** 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

no specific commennts